<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_b_033.html</title>
</head>
<body>
<p>* The company announced the sale of its developed markets pharmaceuticals business.</p>
<p>* The company announced the sale of its animal health business.</p>
<p>* The firm acquired a controlling interest in CFR Pharmaceuticals.</p>
<p>* The firm acquired Veropharm, a Russian pharmaceutical company.</p>
<p>* The Established Pharmaceuticals segment will now focus exclusively on emerging markets.</p>
<p>* Emerging markets sales concentration increased to nearly 50% of total sales.</p>
<p>* The prior year&#x27;s international pediatric nutrition product recall was resolved.</p>
<p>* Three new nutritional manufacturing plants were opened in key global markets.</p>
<p>* A strategic dairy farming alliance was formed with Fonterra in China.</p>
<p>* A new drug-eluting stent, XIENCE Alpine, was launched in the U.S.</p>
<p>* The company disclosed losing U.S. market share for its drug-eluting stents.</p>
<p>* Diabetes Care replaced Established Pharmaceuticals as a primary segment for sales rebates.</p>
<p>* Net actuarial losses for pension benefit plans increased significantly.</p>
<p>* U.S. reimbursement reductions were newly cited as a cause for price declines.</p>
<p>* Weakness in new sub-markets explained the U.S. adult nutrition sales decline.</p>
<p>* The company announced the sale of its developed markets branded generics business.</p>
<p>* An agreement was reached to sell the animal health business.</p>
<p>* Acquired CFR Pharmaceuticals to expand its branded generics presence in Latin America.</p>
<p>* Acquired Veropharm, establishing a manufacturing footprint in Russia.</p>
<p>* Acquired Topera, entering the electrophysiology market.</p>
<p>* Operating results for the newly divested businesses were reclassified to discontinued operations.</p>
<p>* Vascular products began contributing to gross margin improvement, a reversal from the prior year.</p>
<p>* The reason for lower R&amp;D spending changed to the completion of vascular programs.</p>
<p>* Increased SG&amp;A was attributed to new restructuring and acquisition-related costs.</p>
<p>* New restructuring plans were approved to streamline various business operations.</p>
<p>* A rise in interest expense was newly attributed to higher short-term borrowings.</p>
<p>* The company disclosed new impairment charges associated with certain equity investments.</p>
<p>* Debt assumed from the CFR acquisition was extinguished during the year.</p>
<p>* The company executed a one-time repatriation of non-U.S. earnings.</p>
<p>* The Established Pharmaceuticals strategy now focuses on over 300 branded generic projects.</p>
<p>* The division now aims to be first-to-market with new branded generics.</p>
<p>* A new vascular stent, XIENCE Alpine, received regulatory approval and launched.</p>
<p>* A new clinical trial for the Absorb device was started to prove cost-effectiveness.</p>
<p>* Development of future generations of bioresorbable scaffold (BVS) technologies has begun.</p>
<p>* Development of a next-generation MitraClip system is now underway.</p>
<p>* The Supera stent system received US FDA approval for treating peripheral artery disease.</p>
<p>* A new Versaturn guide wire received regulatory clearance in the US and Europe.</p>
<p>* The TECNIS Symfony intraocular lens for cataract surgery was launched in Europe.</p>
<p>* The IRIDICA instrument for rapid pathogen identification was launched in Europe.</p>
<p>* The FreeStyle Libre glucose monitoring system was launched in Europe.</p>
<p>* Cash reinvested abroad is now specifically quantified at over 85%.</p>
<p>* Expected pension funding for the upcoming year has significantly increased.</p>
<p>* Funding sources for investments now explicitly include cash on hand and borrowings.</p>
<p>* A new $3 billion share repurchase program was authorized.</p>
<p>* Working capital decreased due to funding acquisitions and share repurchases.</p>
<p>* Collection of government receivables in southern Europe has improved, reducing exposure.</p>
<p>* A new disclosure was added for risks related to Venezuelan currency.</p>
<p>* A disclosure on a new revenue recognition accounting standard was added.</p>
</body>
</html>
